

AWARD NUMBER: W81XWH-14-1-0539

TITLE: WDR26 in Advanced Breast Cancer: A Novel Regulator of the
P13K/AKT Pathway

PRINCIPAL INVESTIGATOR: Songhai Chen, MD, PhD

CONTRACTING ORGANIZATION: University of Iowa
Iowa City, IA 52242

REPORT DATE: October 2015

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE October 2015		2. REPORT TYPE Annual		3. DATES COVERED 30 Sep 2014 - 29 Sep 2015	
4. TITLE AND SUBTITLE WDR26 in Advanced Breast Cancer: A Novel Regulator of the PI3K/AKT Pathway				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-14-1-0539	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Songhai Chen E-Mail: Songhai-chen@uiowa.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The University of Iowa, Iowa City, IA 52242				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The PI3K/AKT pathway is one of the most deregulated pathways in breast cancers (>70%), and a major contributor to tumor progression. PI3Ks and AKTs comprise of multiple isoforms that play a critical role in a wide variety of physiological progresses. Moreover, during cancer progression, different PI3K and AKT isoforms may have different and even opposite roles. Notably, PI3K β and AKT2 have been identified as the major isoform that contribute to breast cancer growth and metastasis. Yet, it is not yet clear how to specifically target the PI3K β /AKT2 without causing wide spread side effects. In this proposal, we aim to test the hypothesis that WDR26 functions as a novel regulator of the PI3K β /AKT2 pathway, and a previously unidentified marker/therapeutic target in advanced breast cancer, in particular, triple negative breast cancer (TNBC). Our results thus far demonstrated that WDR26 serves as a scaffold that fosters the interaction between G $\beta\gamma$, PI3K β , and AKT2; and in highly malignant and invasive breast tumors, upregulated WDR26 overactivates the PI3K β /AKT2 pathway, promoting breast tumor growth and metastasis. .					
15. SUBJECT TERMS Breast cancer growth and Metastasis, heterotrimeric G protein $\beta\gamma$ subunits, G protein-coupled receptors, signal transduction, PI3K, AKT					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
Unclassified	Unclassified	Unclassified	Unclassified	11	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
1. Introduction.....	2
2. Keywords.....	2
3. Accomplishments.....	2
4. Impact.....	9
5. Changes/Problems.....	9
6. Products.....	9
7. Participants & Other Collaborating Organizations.....	9
8. Special Reporting Requirements.....	9
9. Appendices.....	9

1. Introduction:

Breast cancer is the second most common cause of cancer death in women in the US. Despite recent advances in the development of new treatments (e.g., targeted therapies) limited options are available for patients with advanced breast cancer, in particular, triple negative breast cancer (TNBC). Thus, it is imperative to develop novel approaches for treating advanced breast cancer.

In over 70% of breast cancers, the PI3K/AKT signaling pathway is dysregulated. This pathway transmits signals downstream from critical cell surface receptors, including receptor tyrosine kinase and G protein-coupled receptors (GPCRs) and, when dysregulated, is believed to promote tumor progression, resistance to available therapies and cancer relapse. PI3K/AKT signaling plays a central role in driving many aggressive breast cancers, making it one of the most hotly pursued therapeutic targets for new breast cancer treatments. However, ongoing concerns remain regarding the efficacy and long-term safety of directly inhibiting enzymatic activities that control a wide spectrum of biological processes. Thus, it is imperative that new strategies be developed for regulating, with a high degree of specificity, the signals this pathway emits, so we can harness the power of the PI3Ks and AKTs to control breast cancer.

Our preliminary studies suggest that WDR26 may function as a scaffold that fosters the interaction between G $\beta\gamma$, PI3K β , and AKT2; and in highly malignant and invasive breast tumors, upregulated WDR26 overactivates the PI3K β /AKT2 pathway, promoting breast tumor growth and metastasis. Moreover, WDR26 may serve as a previously unidentified, yet powerful prognostic marker /therapeutic target for advanced TNBC patients. In this proposal, we aim to define precisely the key role of WDR26 in breast tumor (in particular TNBC) development, as well as to determine, using preclinical models of advanced triple negative breast cancer, the therapeutic efficacy of targeting WDR26 with small molecule inhibitors. Our proposed studies could potentially uncover a novel and efficacious approach for developing a new PI3K/AKT-targeted therapy that would improve the outcome for patients affected by advanced breast cancer (in particular, triple negative breast cancer), including the women in the military services. This could be a major breakthrough both in our understanding of the molecular mechanisms that drive TNBC progression and in our effort to eliminate suffering and death caused by advanced breast cancer.

2. **Keywords:** Breast cancer growth and Metastasis, heterotrimeric G protein $\beta\gamma$ subunits, G protein-coupled receptors, signal transduction, PI3K, AKT
3. **Accomplishments:** Summarized below are the accomplishments from research work performed in the 1st yr of this project in direct alignment with the Statement of Work (SOW) schedule.

Task/Milestone 1. Determine how WDR26 promotes PI3K/AKT activation and breast tumor progression. This aim will determine how WDR26 promotes tumor growth and metastasis via dysregulation of the PI3K β /AKT2 pathway. (months 1-24)

Major Goal 1: Assess how WDR26 regulates PI3K/AKT signaling in breast cancer cells. (months 1-12)
1a. Determine WDR26 levels in a panel of breast cancer cell lines. (months 1-4).


Accomplishments: we have determined WDR26 expression in MDA-MB231, DU4475, BT549, MCF7, T47D and MCF10A cell lines. We found that WDR26 is upregulated in triple-negative breast cancer cell lines MDA-MB231, DU4475 and BT549, but not in estrogen receptor positive cell lines MCF7 and T47D, as compared to the non-transformed epithelial cell line MCF10A (Fig. 1). We have not yet confirmed these findings in a larger set of breast cancer cell lines as there was a delay in obtaining these cell lines from ATCC in our cell core facility. We anticipate to complete these studies during the second report period.

1b. Evaluate the role of WDR26 in regulating PI3K β /AKT2 activation. (months 3-9)

Accomplishment: we have shown that downregulation of WDR26 in MDA-MB231, DU4475 or BT549 impaired cell growth (Fig. 2A-D), migration (Fig. 3A-B) and invasion (Fig. 3C). Conversely,

overexpression of WDR26 in MCF7 cells resulted in enhanced cell growth and migration (Fig. 2E and Fig. 3D). Moreover, we showed that WDR26 is required for PI3K/AKT activation as downregulation of WDR26 selectively alleviated GPCR-stimulated AKT phosphorylation (Fig. 4A-B), while overexpression of WDR26 had opposite effects (Fig. 4C).

1c. Dissect how the WDR26 scaffold facilitates G β γ -mediated PI3K β /AKT2 activation (months 6-12). Accomplishment: we showed that WDR26 selectively co-immunoprecipitated with endogenous G β γ , PI3K β and AKT2 in MDA-MB231 cells (Fig. 5A-B). WDR26 binds AKT2 and enhances its interaction with G β γ (Fig. 5C). WDR26 also binds PI3K β and forms a trimeric complex with PI3K β and G β 1 γ 2 (Fig. 5D). We also identified the binding sites of PI3K β (Fig. 5E) and AKT2 (Fig. 5F) on WDR26. Finally, we showed that disruption of the complex formation between WDR26, G β γ , PI3K β and AKT2 in MDA-MB231 cells impaired AKT activation, tumor cell growth and migration (Fig. 6).






Figure 2. WDR26 promotes proliferation of breast cancer cells. A-D, Downregulation of WDR26 inhibited breast cancer cell growth. MDA-MB231 (A-C) or DU4475 (D) cells were transiently transfected with a control (siCT) siRNA or siRNAs targeting two distinct regions of WDR26 (siWDR-1 and siWDR-2) (A) or siWDR-1 (siWDR26) (B-D). The effect on cell growth in Matrigel (A) was determined by phase-contrast imaging, followed by quantification of the size of the colonies. Colony size is expressed as the fraction of that derived from siCT-transfected cells. The effect on cell growth in 2D culture was measured by MTT assays (B and D) or BrdU incorporation assays (C). BrdU incorporation was detected by immunofluorescence staining. Phase contrast (PH) images of cells and fluorescence images of BrdU and nuclear (DAPI) staining are shown in C. Quantitative data showing the level of BrdU incorporation are expressed as the percentage of cells stained with BrdU. *, ** $p < 0.05$ and 0.01 versus siCT, respectively (N=4-5). *Insert*, representative blots showing WDR26 downregulation. E, overexpression of WDR26 promotes MCF7 cell growth. MCF7 cells stably expressing inducible GFP or WDR26 were treated with doxycycline (1 μ g/ml) and cultured in Matrigel for ten days. The size of cell colonies was quantified and expressed as a fold-increase over that of GFP-expressing colonies. * $p < 0.05$ versus GFP (n=4). *Insert*, a representative blot showing the level of WDR26 overexpression. Solid and hollow arrows indicate the ectopic and endogenous WDR26 expression in MCF7 cells, respectively.





Figure 3. WDR26 promotes breast cancer cell migration and invasion. A-C, MDA-MB231 cells were transiently transfected with a control siRNA (siCT) or siRNAs against WDR26 (siWDR26, siWDR26-1 or siWDR26-2). The effects on cell migration were determined by a wound healing assay (A) and transwell migration assay (B) in response to buffer (basal) or chemoattractants, SDF1 α (100 nM), LPA (50 nM), PAR2 agonist peptide (10 μ M) and EGF (50 ng/ml). The effect of LPA on cell invasion was determined in a transwell migration assay with the filter coated with a thin layer of Matrigel (C). *, **, *** $p < 0.05$, 0.01 and 0.001, respectively, *versus* siCT (N=4-6). D, the effect of WDR26 overexpression on MCF7 cell migration. MCF7 cells stably expressing inducible GFP or WDR26 were treated with doxycycline (1 μ g/ml) for 5 days and then subjected to the transwell migration assay as described in B. *, ** $p < 0.05$ and 0.01, respectively, *versus* basal (n=4).







Figure 5. WDR26 fosters the interactions between Gβγ, PI3Kβ and AKT2. A-B, WDR26 is selectively co-immunoprecipitated with endogenous Gβγ, PI3Kβ and AKT2 in MDA-MB231 cells. MDA-MB231 cells expressing FLAG-GFP or FLAG-WDR26 were stimulated with LPA (10 μM) for the indicated time and subjected to immunoprecipitation with an anti-FLAG antibody. Co-immunoprecipitated proteins were detected with the indicated antibodies. Representative blots are shown in A and quantitative data from three independent experiments are shown in B. The amount of immunoprecipitated proteins is expressed as the percentage of total proteins in the lysates, with the background binding from FLAG-GFP immunoprecipitates subtracted. * $p < 0.05$ versus 0 min. C, WDR26 binds AKT2 and enhances its interaction with Gβγ. HEK293 cells were transiently transfected with HA-AKT2 and FLAG-Gβ1γ2 or Myc-WDR26, or FLAG-Gβ1γ2 plus Myc-WDR26. Cell lysates were immunoprecipitated with an anti-HA antibody. D, WDR26 binds PI3Kβ and forms a trimeric complex with PI3Kβ and Gβ1γ2. MDA-MB231 cells transduced with adenoviruses encoding the indicated proteins were subjected to co-immunoprecipitation assays as described in C. E-F, the binding sites of PI3Kβ and AKT2 on WDR26. FLAG-GFP, FLAG-WDR26 and its deletion mutants were transiently co-expressed with PI3Kβ in MDA-MB231 (E) or AKT2 in HEK293 (F) cells, and were immunoprecipitated from cell lysates with an anti-FLAG antibody. The bands corresponding to GFP, WDR26, and its mutants are indicated by asterisks. A schematic representation of the WDR26 structure is shown in the top panel of E.



4. **Impact:** our results thus far identify a novel mechanism regulating GPCR-dependent activation of the PI3K/AKT signaling axis in breast tumor cells, and pinpoint WDR26 as a potential therapeutic target for breast cancer.
5. **Change or problems:** nothing to report.
6. **Products:** nothing to report.
7. **Participants & other collaborating organizations:**
Yuanchao Ye, PhD, a postdoctoral fellow, has been working on this project for the last 12 months. She has performed the work described here.
8. **Special Reporting Requirements:** n/a
9. **Appendices:** none